Revolutionary Field Cycling Imaging Scanner Trialed for Brain Tumors

A groundbreaking new medical imaging technology, known as Field Cycling Imaging (FCI), is currently being trialed for brain tumor patients in a world-first initiative led by researchers at the University of Aberdeen and NHS Grampian. This innovative scanner, which operates on low and ultra-low magnetic fields, has received £350,000 in funding from the Scottish government to develop unprecedented imaging capabilities for glioblastoma, the most common and aggressive brain tumor affecting over 3,000 new patients in the UK annually.

The urgency of this research is underscored by the grim prognosis associated with glioblastoma; approximately half of the affected patients succumb to the disease within 15 months of diagnosis, even after undergoing extensive treatment options, such as surgery, radiotherapy, and chemotherapy. Professor Anne Kiltie, who is spearheading the study, emphasized the potential of FCI to revolutionize patient care. “If we can detect true tumor progression early, we can swap the patient to a potentially more beneficial type of chemotherapy,” she noted. This capability could lead to improved treatment outcomes and enhanced quality of life for patients.

Field Cycling Imaging is derived from traditional MRI technology but boasts distinct advantages. Unlike conventional scanners, FCI can vary the strength of its magnetic field during scans, allowing for the extraction of more comprehensive information about the tissues being examined. Moreover, this technology can identify tumors without the need for contrast dyes, which can pose risks of kidney damage and allergic reactions in some patients.

Historically, full-body MRI scanners were first developed at the University of Aberdeen 50 years ago, but this specialized FCI scanner represents a significant advancement, being the only one of its kind used on patients globally. The technology has previously demonstrated efficacy in detecting tumors in breast tissue and assessing brain damage in stroke patients, suggesting a promising application in oncology.

The current trial aims to assess glioblastoma patients undergoing chemotherapy following surgery and chemoradiotherapy, with a focus on determining whether FCI can differentiate between tumor growth and pseudo-progression—an appearance of tumor growth that is, in fact, non-cancerous tissue. This distinction is crucial as it could prevent premature cessation of effective chemotherapy, thereby improving overall patient prognosis.

The implications of this research extend beyond individual patient care. As highlighted by the charity Friends of ANCHOR, this study exemplifies the pioneering work emerging from the University of Aberdeen. The potential to establish a reliable method for identifying progressive disease could facilitate the development and evaluation of new treatments, addressing the limited options currently available for glioblastoma patients.

In conclusion, the trial of FCI for brain tumor patients represents a significant step forward in medical imaging and cancer treatment. With continued research and successful implementation, this innovative technology could enhance the efficiency of treatment pathways, reduce patient anxiety, and ultimately improve outcomes for individuals battling glioblastoma across Scotland and beyond.